DK3206692T3 - Behandling af fedtleversygdom med glucocorticoid- og mineralcorticoid-receptorantagonister - Google Patents

Behandling af fedtleversygdom med glucocorticoid- og mineralcorticoid-receptorantagonister Download PDF

Info

Publication number
DK3206692T3
DK3206692T3 DK15851238.4T DK15851238T DK3206692T3 DK 3206692 T3 DK3206692 T3 DK 3206692T3 DK 15851238 T DK15851238 T DK 15851238T DK 3206692 T3 DK3206692 T3 DK 3206692T3
Authority
DK
Denmark
Prior art keywords
glucocorticoid
treatment
receptor antagonists
liver disease
fatty liver
Prior art date
Application number
DK15851238.4T
Other languages
Danish (da)
English (en)
Inventor
Joseph K Belanoff
Hazel Hunt
Den Heuvel Jose Van
Onno C Meijer
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Application granted granted Critical
Publication of DK3206692T3 publication Critical patent/DK3206692T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK15851238.4T 2014-10-15 2015-10-14 Behandling af fedtleversygdom med glucocorticoid- og mineralcorticoid-receptorantagonister DK3206692T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462064358P 2014-10-15 2014-10-15
US201462092041P 2014-12-15 2014-12-15
PCT/US2015/055487 WO2016061195A1 (en) 2014-10-15 2015-10-14 Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

Publications (1)

Publication Number Publication Date
DK3206692T3 true DK3206692T3 (da) 2024-04-29

Family

ID=55747256

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15851238.4T DK3206692T3 (da) 2014-10-15 2015-10-14 Behandling af fedtleversygdom med glucocorticoid- og mineralcorticoid-receptorantagonister

Country Status (22)

Country Link
US (5) US10238659B2 (enExample)
EP (2) EP4353310A3 (enExample)
JP (1) JP6761410B2 (enExample)
KR (1) KR102435956B1 (enExample)
CN (2) CN111557942B (enExample)
AU (1) AU2015333645B2 (enExample)
BR (1) BR112017007860B1 (enExample)
CA (1) CA2964625C (enExample)
DK (1) DK3206692T3 (enExample)
ES (1) ES2978871T3 (enExample)
FI (1) FI3206692T3 (enExample)
IL (1) IL251729B (enExample)
MX (1) MX2017004943A (enExample)
NZ (1) NZ731060A (enExample)
PH (1) PH12017500710B1 (enExample)
PL (1) PL3206692T3 (enExample)
PT (1) PT3206692T (enExample)
RU (1) RU2718921C2 (enExample)
SG (1) SG11201703024VA (enExample)
UA (1) UA123537C2 (enExample)
WO (1) WO2016061195A1 (enExample)
ZA (1) ZA201702813B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111557942B (zh) 2014-10-15 2023-10-03 科赛普特治疗学股份有限公司 使用糖皮质激素和盐皮质激素受体拮抗剂的脂肪肝疾病治疗
CN112236416B (zh) * 2018-06-04 2024-03-01 科赛普特治疗公司 嘧啶环己烯基糖皮质激素受体调节剂
KR20210153056A (ko) 2019-03-18 2021-12-16 리네트 케이. 니만 인슐린 감수성 개선 방법
EP4146631A4 (en) * 2020-05-06 2024-06-19 Corcept Therapeutics Incorporated POLYMORPHS OF PYRIMIDINE-CYCLOHEXYL-GLUCOCORTICOID RECEPTOR MODULATORS
IL297840A (en) * 2020-05-06 2023-01-01 Corcept Therapeutics Inc Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators
KR102481705B1 (ko) * 2020-08-04 2022-12-27 연세대학교 산학협력단 트리아졸 유도체를 유효성분으로 포함하는 간 섬유증의 예방 또는 치료용 조성물
CN116848092A (zh) * 2020-12-21 2023-10-03 科赛普特治疗公司 制备嘧啶环己基糖皮质激素受体调节剂的方法
EP4333848A4 (en) * 2021-05-05 2025-03-19 Corcept Therapeutics Incorporated Methods for reducing liver fat and treating fatty liver disease
WO2025174745A1 (en) * 2024-02-12 2025-08-21 Corcept Therapeutics Incorporated MIRICORILANT TREATMENT FOR FATTY LIVER DISEASES and its EFFECTS on LIVER FAT CONTENT, FATTY ACIDS, ACYLGLYCEROLS, and SECONDARY BILE ACIDS
WO2025255357A1 (en) * 2024-06-06 2025-12-11 Corcept Therapeutics Incorporated Methods for preparing and maintaining livers and portions thereof for liver transplantation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2153546A (en) 1936-07-29 1939-04-11 Universal Draft Gear Attachmen Hand brake actuating mechanism
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
GB0213745D0 (en) * 2002-06-14 2002-07-24 Univ Edinburgh Enzyme
AU2003251970A1 (en) 2002-07-18 2004-02-09 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
ATE463479T1 (de) 2005-05-18 2010-04-15 Merck Sharp & Dohme D-homoandrosta-17-yl-carbamat-derivate als selektive glucocorticoid-rezeptor-liganden
US8389472B2 (en) 2005-08-19 2013-03-05 Amylin Pharmaceuticals, Llc Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
US20070066557A1 (en) * 2005-09-19 2007-03-22 Monia Brett P Modulation of glucocorticoid receptor expression
GB0601092D0 (en) * 2006-01-19 2006-03-01 Daniolabs Ltd The Prevention Of Systemic Side-Effects Of Glucocorticoids
HUE026057T2 (en) 2006-05-09 2016-05-30 Genzyme Corp Procedures for the Treatment of Fatty Liver Disease, which comprises inhibition of glycosphingolipid synthesis
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
CN101679445A (zh) * 2007-04-13 2010-03-24 先灵公司 嘧啶二酮衍生物及其应用
WO2009155481A1 (en) 2008-06-20 2009-12-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
PT2414356E (pt) 2009-04-03 2015-11-23 Hoffmann La Roche Composições de {3-[5-(4-cloro-fenil)-1h-pirrol[2,3-b]piridin-3-carbonil]-2,4-difluoro-fenil}-amida do ácido propano-1-sulfónico e utilizações das mesmas
ES2563444T3 (es) * 2011-03-18 2016-03-15 Corcept Therapeutics, Inc. Moduladores del receptor de glucocorticoide de tipo pirimidina ciclohexilo
CN111557942B (zh) 2014-10-15 2023-10-03 科赛普特治疗学股份有限公司 使用糖皮质激素和盐皮质激素受体拮抗剂的脂肪肝疾病治疗

Also Published As

Publication number Publication date
CA2964625C (en) 2023-03-07
RU2017114596A (ru) 2018-11-15
WO2016061195A1 (en) 2016-04-21
EP3206692A4 (en) 2018-05-30
IL251729A0 (en) 2017-06-29
AU2015333645A1 (en) 2017-05-04
JP2017531013A (ja) 2017-10-19
MX2017004943A (es) 2017-07-19
CN107106562A (zh) 2017-08-29
PH12017500710B1 (en) 2024-01-17
KR102435956B1 (ko) 2022-08-23
US20160106749A1 (en) 2016-04-21
RU2718921C2 (ru) 2020-04-15
KR20170066646A (ko) 2017-06-14
PH12017500710A1 (en) 2017-10-09
CN111557942B (zh) 2023-10-03
CA2964625A1 (en) 2016-04-21
US12226417B2 (en) 2025-02-18
JP6761410B2 (ja) 2020-09-23
EP3206692B1 (en) 2024-04-03
ZA201702813B (en) 2019-05-29
NZ731060A (en) 2023-07-28
EP3206692A1 (en) 2017-08-23
US20230218621A1 (en) 2023-07-13
UA123537C2 (uk) 2021-04-21
IL251729B (en) 2020-03-31
US11590135B2 (en) 2023-02-28
RU2017114596A3 (enExample) 2019-05-08
US10238659B2 (en) 2019-03-26
PL3206692T3 (pl) 2024-07-22
EP4353310A2 (en) 2024-04-17
ES2978871T3 (es) 2024-09-23
US20210085682A1 (en) 2021-03-25
AU2015333645B2 (en) 2020-01-30
FI3206692T3 (fi) 2024-05-06
US10881660B2 (en) 2021-01-05
US20250221995A1 (en) 2025-07-10
BR112017007860B1 (pt) 2023-03-07
CN111557942A (zh) 2020-08-21
CN107106562B (zh) 2020-08-18
EP4353310A3 (en) 2024-06-19
US20190151318A1 (en) 2019-05-23
BR112017007860A2 (pt) 2018-01-16
PT3206692T (pt) 2024-04-30
SG11201703024VA (en) 2017-05-30

Similar Documents

Publication Publication Date Title
IL285101A (en) Antibodies targeting g-protein coupled receptor and methods of use
IL283761A (en) Compounds and methods for the targeted degradation of androgen receptor
DK3206692T3 (da) Behandling af fedtleversygdom med glucocorticoid- og mineralcorticoid-receptorantagonister
IL264607A (en) Chimeric antigen receptors targeting bcma and methods of use thereof
IL262041A (en) Chimeric receptors and methods of use thereof
IL254039A0 (en) Anti-pvrig antibodies and methods of use
IL251970B (en) Anti-cd79b antibodies and methods of use
EP4212536C0 (en) BENZOXAZEPINE OXAZOLIDINONE COMPOUNDS AND METHODS OF USE
PL3353210T3 (pl) Przeciwciała anty-TIGIT i sposoby stosowania
CL2016002462A1 (es) Anticuerpos anti-ox40 y métodos de uso
IL249092A0 (en) Anti-gitr antibodies and methods of use thereof
PL3215532T3 (pl) Przeciwciała anty-TIM3 i sposoby ich zastosowania
KR20180084817A (ko) 항-siglec-9 항체 및 이의 이용 방법
PT3368534T (pt) Ditosilato de valbenazina e polimorfos do mesmo
PT3548033T (pt) Compostos e respectivos métodos de utilização
PL3250610T3 (pl) Przeciwciała anty-FcRn i sposoby ich stosowania
IL251505A0 (en) Neuroactive compounds and methods of use thereof
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
PT3160964T (pt) Moduladores dos receptores de arilo e métodos de fabrico e utilização dos mesmos
DK3280710T3 (da) Fremgangsmåde til fremstilling af androgenreceptorantagonister og mellemprodukter deraf
DK3166911T3 (da) Inkorporering af biologiske midler i gødning
IL249582B (en) Use of materials incorporating microparticles for avoiding the proliferation of contaminants
DK3297653T3 (da) Behandling af postbariatrisk hypoglykæmi med glp-1-antagonister
EP3398262A4 (en) MICRO-OUTER CHARACTERIZATION AND SELECTION
IL260851A (en) Somatostatin receptor antagonist compounds and methods of using the same